Your browser doesn't support javascript.
loading
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Shao, Y-Y; Chen, B-B; Ou, D-L; Lin, Z-Z; Hsu, C-H; Wang, M-J; Cheng, A-L; Hsu, C.
  • Shao YY; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Chen BB; National Taiwan University Cancer Center, Taipei, Taiwan.
  • Ou DL; Departments of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Lin ZZ; Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan.
  • Hsu CH; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Wang MJ; National Taiwan University Cancer Center, Taipei, Taiwan.
  • Cheng AL; Departments of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Hsu C; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Aliment Pharmacol Ther ; 46(8): 722-730, 2017 10.
Article en En | MEDLINE | ID: mdl-28815645
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Talidomida / Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Talidomida / Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article